Latest Agomelatine Stories
A drug that regulates your body clock may also be able to treat depression.
PARIS, January 24 /PRNewswire/ -- The European Commission has granted marketing authorisation for Servier's Valdoxan(R) /Thymanax(R) (agomelatine), the first melatonergic antidepressant for the treatment of adult patients with major depressive episodes. "There is still great scope for improved therapies to treat the devastating effects of depression," said Professor Goodwin from Warneford Hospital, Oxford, United Kingdom.
Marinus Pharmaceuticals, a developer of specialty therapeutics to treat serious neurological, psychiatric and pain disorders, has appointed John Krayacich as its new president and CEO.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.